Theriva Biologics (NYSEAMERICAN:TOVX) Trading 2.5% Higher – Time to Buy?

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) traded up 2.5% during mid-day trading on Wednesday . The company traded as high as $0.3321 and last traded at $0.33. 1,510,601 shares changed hands during mid-day trading, a decline of 97% from the average session volume of 45,293,048 shares. The stock had previously closed at $0.3219.

Analyst Ratings Changes

Separately, Maxim Group upgraded shares of Theriva Biologics from a “hold” rating to a “buy” rating and set a $1.00 target price for the company in a research note on Tuesday, March 31st. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $1.00.

Theriva Biologics Price Performance

The company has a debt-to-equity ratio of 0.11, a current ratio of 1.63 and a quick ratio of 1.63. The stock has a market capitalization of $9.82 million, a price-to-earnings ratio of -0.01 and a beta of 1.17. The stock’s 50 day simple moving average is $0.26 and its 200-day simple moving average is $0.24.

Theriva Biologics (NYSEAMERICAN:TOVX) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.05) earnings per share for the quarter.

Institutional Trading of Theriva Biologics

A hedge fund recently raised its stake in Theriva Biologics stock. Geode Capital Management LLC lifted its position in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) by 651.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 212,087 shares of the company’s stock after buying an additional 183,878 shares during the quarter. Geode Capital Management LLC owned about 0.63% of Theriva Biologics worth $45,000 as of its most recent filing with the Securities and Exchange Commission. 6.17% of the stock is currently owned by institutional investors.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.